Boehringer Ingelheim GmbH, of Ingelheim, Germany. and Indianapolis-based Eli Lilly and Co. said they will conduct two outcome trials investigating the diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure.